keyword
MENU ▼
Read by QxMD icon Read
search

hepatocellular carcinoma stage system

keyword
https://www.readbyqxmd.com/read/28099898/the-best-strategy-for-hcc-patients-at-each-bclc-stage-a-network-meta-analysis-of-observational-studies
#1
REVIEW
Lei Chang, Yitao Wang, Jibo Zhang, Tao Guo
BACKGROUND AND AIMS: Currently, the Barcelona Clinic Liver Cancer staging system remains huge controversies in the management of hepatocellular carcinoma. To determine the best therapeutic strategy for patients at each stage, we conducted a network meta-analysis and aimed to provide a new treatment concept. MATERIALS AND METHODS: PubMed, Embase and Cochrane Library database were searched for observational studies up to August 31, 2016. We extracted data on overall survival rate from studies that compared various strategies for use with patients at different stages...
January 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28097096/impact-of-different-embolic-agents-for-transarterial-chemoembolization-tace-procedures-on-systemic-vascular-endothelial-growth-factor-vegf-levels
#2
Andreas Schicho, Claus Hellerbrand, Kristina Krüger, Lukas P Beyer, Walter Wohlgemuth, Christoph Niessen, Ernst Hohenstein, Christian Stroszczynski, Philippe L Pereira, Philipp Wiggermann
Background and Aims: Intermediate stage hepatocellular carcinoma (HCC) can be treated by transarterial chemoembolization (TACE). However, there appear to be side effects, such as induction of proangiogenic factors, e.g. vascular endothelial growth factor (VEGF), which have been shown to be associated with a poor prognosis. This prospective study was designed to compare serum VEGF level response after TACE with different embolic agents in patients with HCC. Methods: Patients were assigned to one of three different TACE regimens: degradable starch microspheres (DSM) TACE, drug-eluting bead (DEBDOX) TACE or Lipiodol TACE (cTACE)...
December 28, 2016: Journal of Clinical and Translational Hepatology
https://www.readbyqxmd.com/read/28095820/microvascular-invasion-has-limited-clinical-values-in-hepatocellular-carcinoma-patients-at-barcelona-clinic-liver-cancer-bclc-stages-0-or-b
#3
Cheng Huang, Xiao-Dong Zhu, Yuan Ji, Guang-Yu Ding, Guo-Ming Shi, Ying-Hao Shen, Jian Zhou, Jia Fan, Hui-Chuan Sun
BACKGROUND: Microvascular invasion (MVI) is recognized as a prognostic factor associated with poor outcome in hepatocellular carcinoma (HCC) patients after curative resection. It remains unclear, however, whether MVI can provide prognostic information for patients at a specific tumor stage. METHODS: Consecutive HCC patients who underwent curative resection in years of 2007 and 2008 (discovery cohort) were enrolled in this retrospective study. Patients were stratified by the Barcelona Clinic Liver Cancer (BCLC) staging system...
January 17, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28087980/the-significance-of-glypican-3-expression-profiling-in-the-tumor-cellular-origin-theoretical-system-for-hepatocellular-carcinoma-progression
#4
Ran Xue, Jiliang Feng, Qinghua Meng, Fudong Lv, Yueke Zhu, Hongwei Yu, Shijie Zhang, Chenzhao Song, Lin Sun, Zhujun Yue, Shuai Feng, Ruiwen Che, Qian Xiang, Xiaodan Jing
AIMS: Glypican-3(GPC3) expression is correlated with poor prognosis and progression in hepatocellular carcinoma (HCC). HCC progression can be associated with the differentiation status of tumor cell before malignant transformation. Our aim was to investigate the dynamic expression of GPC3 during tumor cells differentiation and to explore the role and theoretical significance of GPC3 in malignant essence of HCC. METHODS: The expressions of tissue GPC3 and alpha-fetoprotein (AFP) were detected by immunohistochemical staining...
January 14, 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28087399/advances-with-using-crispr-cas-mediated-gene-editing-to-treat-infections-with-hepatitis-b-virus-and-hepatitis-c-virus
#5
REVIEW
Buhle Moyo, Kristie Bloom, Tristan Scott, Abdullah Ely, Patrick Arbuthnot
Chronic infections with hepatitis B and hepatitis C viruses (HBV and HCV) account for the majority of cases of cirrhosis and hepatocellular carcinoma. Current therapies for the infections have limitations and improved efficacy is necessary to prevent complications in carriers of the viruses. In the case of HBV persistence, the replication intermediate comprising covalently closed circular DNA (cccDNA) is particularly problematic. Licensed therapies have little effect on cccDNA and HBV replication relapses following treatment withdrawal...
January 10, 2017: Virus Research
https://www.readbyqxmd.com/read/28081593/percutaneous-cryoablation-for-hepatocellular-carcinoma
#6
Kyoung Doo Song
Local ablation therapy is considered as a conventional treatment option for patients with early stage hepatocellular carcinoma (HCC). Although radiofrequency (RF) ablation is widely used for HCC, the use of cryoablation has been increasing as newer and safer cryoablation systems have developed. The thermodynamic mechanism of freezing and thawing used in cryoablation is the Joule-Thomson effect. Cryoablation destroys tissue via direct tissue destruction and vascular-related injury. A few recent comparative studies have shown that percutaneous cryoablation for HCCs is comparable to percutaneous RF ablation in terms of long term therapeutic outcomes and complications...
December 2016: Clinical and Molecular Hepatology
https://www.readbyqxmd.com/read/28073159/polymeric-immunoglobulin-receptor-promotes-tumor-growth-in-hepatocellular-carcinoma
#7
Xihua Yue, Jing Ai, Yang Xu, Yi Chen, Min Huang, Xinying Yang, Bo Hu, Haotian Zhang, Changxi He, Xinrong Yang, Weiguo Tang, Xia Peng, Liwei Dong, Hongyang Wang, Jia Fan, Jian Ding, Meiyu Geng
: Deregulation of the immune system is believed to contribute to cancer malignancy, which has led to recent therapeutic breakthroughs facilitating antitumor immunity. In a malignant setting, immunoglobulin receptors, which are fundamental components of the human immune system, fulfill paradoxical roles in cancer pathogenesis. This study describes a previously unrecognized pro-oncogenic function of polymeric immunoglobulin receptor (pIgR) in the promotion of cell transformation and proliferation...
January 10, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28050238/immune-function-biomarker-quantiferon-monitor-is-associated-with-infection-risk-in-cirrhotic-patients
#8
Siddharth Sood, Lijia Yu, Kumar Visvanathan, Peter William Angus, Paul John Gow, Adam Gareth Testro
AIM: To investigate whether a novel immune function biomarker QuantiFERON-Monitor (QFM) can identify cirrhotic patients at greatest risk of infection. METHODS: Adult cirrhotic patients on the liver transplant waiting list were recruited for this observational cohort study from a tertiary liver transplant referral unit. The immune function biomarker, QFM was performed using the same method as the widely available Quantiferon-gold assay, and measures output in interferon gamma in IU/mL after dual stimulation of the innate and adaptive immune systems...
December 18, 2016: World Journal of Hepatology
https://www.readbyqxmd.com/read/28042136/epidemiology-and-treatment-of-hepatocellular-carcinoma-in-thailand
#9
REVIEW
Soonthorn Chonprasertsuk, Ratha-Korn Vilaichone
Hepatocellular carcinoma (HCC) is the most frequent type of malignant liver tumor in Thailand. The high incidence rate of HCC reflects from chronic HBV infection in this endemic area. Some patients are asymptomatic at presentation whereas many of them presented at advanced stage of HCC with limited treatment options and grave outcome. The Barcelona Clinic Liver Cancer (BCLC) staging system and management allocation for HCC is widely accepted and used in many international guidelines including Thailand. Curative treatment is expected in early stage of HCC while palliative treatment, combination treatment and best supportive care are offered to advanced stage of HCC...
January 1, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28039690/the-effect-of-guidelines-in-surgical-decision-making-the-paradigm-of-hepatocellular-carcinoma
#10
Demetrios Moris, Spyridon Vernadakis, Alexandros Papalampros, Athanasios Petrou, Dimitrios Dimitroulis, Eleftherios Spartalis, Evangelos Felekouras, John J Fung
It is not inconceivable to envision surgeons, offering extended liver resection in patients beyond the Barcelona Clinic Liver Cancer (BCLC) staging system criteria with intermediate/advanced hepatocellular carcinoma (HCC), to be found negligent since extensive liver resection is correlated with increased morbidity compared to conservative or palliative treatment. Given that no other classification system than BCLC has been adopted widely for HCC staging and treatment, a revision of the BCLC algorithm and clinical guidelines should be tailored using new molecular and clinical treatment algorithms, as well as including patient's preferences...
November 2016: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/28035063/perioperative-plasma-glypican-3-level-may-enable-prediction-of-the-risk-of-recurrence-after-surgery-in-patients-with-stage-i-hepatocellular-carcinoma
#11
Kazuya Ofuji, Keigo Saito, Shiro Suzuki, Manami Shimomura, Hirofumi Shirakawa, Daisuke Nobuoka, Yu Sawada, Mayuko Yoshimura, Nobuhiro Tsuchiya, Mari Takahashi, Toshiaki Yoshikawa, Yoshitaka Tada, Masaru Konishi, Shinichiro Takahashi, Naoto Gotohda, Yasunari Nakamoto, Tetsuya Nakatsura
Glypican-3 (GPC3) is a glycosylphosphatidylinositol-anchored cell surface protein overexpressed in hepatocellular carcinoma(HCC), and its overexpression is associated with poor prognosis. The diagnostic potential of GPC3 as a serum marker has been reported. In the present study, we evaluated the usefulness of plasma GPC3 as a predictor for recurrence after surgical resection in stage I HCC patients by newly developed an enzyme-linked immunosorbent assay (ELISA) system. Current study demonstrated that high levels of preoperative plasma GPC3 patients tended to experience postoperative recurrence...
December 27, 2016: Oncotarget
https://www.readbyqxmd.com/read/28027429/intrahepatic-angiopoietin-2-correlates-with-chronic-hepatitis-c-progression-and-is-induced-in-hcv-replicon-systems
#12
Ángel Hernández-Bartolomé, Rosario López-Rodríguez, Luisa García-Buey, Samuel Martín-Vílchez, Yolanda Rodríguez-Muñoz, María Jesús Borque, Leticia González-Moreno, Yolanda Real-Martínez, Jorge Mendoza-Ridruejo, Elena Martín-Pérez, Ricardo Moreno-Otero, Paloma Sanz-Cameno
INTRODUCTION & AIMS: Chronic hepatitis C (CHC) is a major cause of cirrhosis and hepatocellular carcinoma and angiogenesis is closely related to the pathogenesis and progression of different chronic liver diseases (CLD). Thus, the intrahepatic expression of angiopoietins 1 and 2 (Ang1 and Ang2), as relevant mediators of pathological angiogenesis in several CLD, was investigated. Additionally, the differential influence of structural and non-structural genomic regions of HCV on the expression of angiopoietins and the possible signaling involved were studied...
December 27, 2016: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28012284/validity-of-the-barcelona-clinic-liver-cancer-and-hong-kong-liver-cancer-staging-system-for-hepatocellular-carcinoma-in-singapore
#13
Li Kim E Selby, Rosanna X Y Tay, Winston W L Woon, Jee Keem Low, Wang Bei, Vishalkumar G Shelat, Tony C Y Pang, Sameer P Junnarkar
In the management of hepatocellular carcinomas (HCC), staging of the disease plays a vital part. Many groups have developed different staging systems that can be adopted for the management of HCC. Although numerous comparisons have been made, because of patient selection criteria and disease heterogeneity, there is currently no worldwide consensus on the use of any given model as the standard for classifying HCC. The reason for differences in approach to HCC can certainly be attributed to the inherent clinical and biological heterogeneity, but can also be attributed to differences in how clinicians and researchers view the cancer...
December 24, 2016: Journal of Hepato-biliary-pancreatic Sciences
https://www.readbyqxmd.com/read/28009759/outcomes-of-simultaneous-liver-kidney-transplantation-in-patients-with-hepatocellular-carcinoma
#14
Nicole Rich, Bekir Tanriover, Amit G Singal, Jorge A Marrero
BACKGROUND: The frequency of simultaneous liver kidney (SLK) transplantation has increased following the implementation of the model for end-stage liver disease system for liver transplantation (LT). There is a paucity of data evaluating SLK outcomes in patients undergoing LT for hepatocellular carcinoma (HCC). Our aim was to compare outcomes between patients with HCC who underwent SLK and those who received SLK for other indications. METHODS: We performed a retrospective analysis of adult recipients receiving SLK between 2002 and 2013 from the United Network for Organ Sharing registry...
January 2017: Transplantation
https://www.readbyqxmd.com/read/27997198/in-vivo-drug-delivery-performance-of-lipiodol-based-emulsion-or-drug-eluting-beads-in-patients-with-hepatocellular-carcinoma
#15
Elsa Lilienberg, Ilse R Dubbelboer, Amar Karalli, Rimma Axelsson, Torkel B Brismar, Charlotte Ebeling Barbier, Agneta Norén, Frans Duraj, Mikael Hedeland, Ulf Bondesson, Erik Sjögren, Per Stål, Rickard Nyman, Hans Lennernäs
Doxorubicin (DOX) delivered in a lipiodol-based emulsion (LIPDOX) or in drug-eluting beads (DEBDOX) is used as palliative treatment in patients with intermediate-stage hepatocellular carcinoma (HCC). The primary objective of this study was to evaluate the in vivo delivery performance of DOX from LIPDOX or DEBDOX in HCC patients using the local and systemic pharmacokinetics of DOX and its main metabolite doxorubicinol (DOXol). Urinary excretion of DOX and DOXol and their short-term safety and antitumor effects were also evaluated...
January 5, 2017: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/27994769/targeting-hepatocellular-carcinoma-what-did-we-discover-so-far
#16
REVIEW
Ana Filipa Brito, Ana Margarida Abrantes, José Guilherme Tralhão, Maria Filomena Botelho
Hepatocellular carcinoma (HCC) is increasingly considered an issue of global importance. Its rates of incidence and mortality have been markedly increasing over the last decades. Among risk factors, some should be highlighted, namely the infections by hepatitis B and C virus, as well as clinical cases of cirrhosis. HCC is characterized as asymptomatic disease in the initial stages which most often leads to a late diagnosis. At molecular and genetic level HCC represents a highly complex tumor entity, including a wide variety of mutations, thus accounting for different mechanisms of resistance towards therapeutic approaches...
October 10, 2016: Oncology Reviews
https://www.readbyqxmd.com/read/27968849/a-novel-risk-score-mcct-to-guide-decision-for-treatment-of-advanced-hepatocellular-carcinoma-with-transarterial-chemoembolisation-a-derivation-and-validation-study
#17
Yong-Fa Zhang, Ming Shi, Rong-Ping Guo
BACKGROUND: Transarterial chemoembolisation (TACE) is still widely used to treat patients with advanced hepatocellular carcinoma who have no access to sorafenib in Asia. However, the indication of TACE for these patients has yet to be established. We established an objective point score to guide this decision in patients with advanced-stage hepatocellular carcinoma. METHODS: We developed a scoring system (MCCT score) based on preoperative data from a cohort of 422 patients receiving TACE as the first treatment for advanced hepatocellular carcinoma from 2006 to 2013 at Sun Yat-sen University Cancer Center, Guangzhou, China...
October 2016: Lancet
https://www.readbyqxmd.com/read/27957638/early-perfusion-changes-within-1-week-of-systemic-treatment-measured-by-dynamic-contrast-enhanced-mri-may-predict-survival-in-patients-with-advanced-hepatocellular-carcinoma
#18
Bang-Bin Chen, Chao-Yu Hsu, Chih-Wei Yu, Po-Chin Liang, Chiun Hsu, Chih-Hung Hsu, Ann-Lii Cheng, Tiffany Ting-Fang Shih
OBJECTIVES: To correlate early changes in the parameters of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) within 1 week of systemic therapy with overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC). METHODS: Eighty-nine patients with advanced HCC underwent DCE-MRI before and within 1 week following systemic therapy. The relative changes of six DCE-MRI parameters (Peak, Slope, AUC, Ktrans, Kep and Ve) of the tumours were correlated with OS using the Kaplan-Meier model and the double-sided log-rank test...
December 12, 2016: European Radiology
https://www.readbyqxmd.com/read/27955729/malignant-tumors-of-the-liver-in-children
#19
Daniel C Aronson, Rebecka L Meyers
This article aims to give an overview of pediatric liver tumors; in particular of the two most frequently occurring groups of hepatoblastomas and hepatocellular carcinomas. Focus lays on achievements gained through worldwide collaboration. We present recent advances in insight, treatment results, and future questions to be asked. Increasing international collaboration between the four major Pediatric Liver Tumor Study Groups (SIOPEL/GPOH, COG, and JPLT) may serve as a paradigm to approach rare tumors. This international effort has been catalyzed by the Children's Hepatic tumor International Collaboration (CHIC) formation of a large collaborative database...
October 2016: Seminars in Pediatric Surgery
https://www.readbyqxmd.com/read/27942837/refining-prognosis-in-patients-with-hepatocellular-carcinoma-through-incorporation-of-metabolic-imaging-biomarkers
#20
Satoshi Takeuchi, Eric M Rohren, Reham Abdel-Wahab, Lianchun Xiao, Jeffrey S Morris, Homer A Macapinlac, Manal M Hassan, Ahmed O Kaseb
PURPOSE: (18)F-fluorodeoxyglucose positron emission tomopraphy/computed tomography (FDGPET/CT) has been proven to be useful for imaging many types of cancer; however, its role is not well defined in hepatocellular carcinoma (HCC). We assessed the prognostic value of metabolic imaging biomarkers as established by baseline pretreatment FDG PET/CT in patients with HCC. METHODS: We retrospectively analyzed the records of patients with HCC who underwent FDG PET/CT before initial treatment from May 2013 through May 2014...
December 12, 2016: European Journal of Nuclear Medicine and Molecular Imaging
keyword
keyword
66281
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"